US FDA’s Breakneck Approval Pace Clashes With Advisory Committee Mandate
• By Michael McCaughan
US FDA has been pressing the "Skip AdComs" button on its drug reviews, leading to faster approvals for sponsors, but fewer opportunities to comment for outside stakeholders. • Source: Photo illustration by Jean Marie Smith
